As a speaker at the AIM at Melanoma 9th Los Angeles Melanoma Symposium for patients and caregivers on May 19, 2018, Dr. Omid Hamid interviews with AIM at Melanoma to provide attendees with an introduction to the topics he covered at the live event. Dr. Omid Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics. Through his role as the Chief of Immunotherapy and Translational Research, patients at The Angeles Clinic have benefited from first in class, paradigm-shifting drugs.Click here to read Q&A with Omid Hamid, MD#Melanoma #Journalarticle #CollaborativePartner #ClinicalTrials #ImmuneCheckpointInhibitors #Patient #PatientAdvocate #2018#AIMatMelanoma